5 active not recruiting, 1 recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent WHO Grade 2 Glioma: new trials by email Literature Review of Recurrent WHO Grade 2 Glioma trials Research Report on Recurrent WHO Grade 2 Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma | Phase 1 | Recruiting | Northwestern University | 22 | 2024-07-23 | 2026-09-09 |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2024-01-04 | 2026-10-15 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment - Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 300 | 2021-02-16 | 2026-07-02 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
Glioma (4) · Ependymoma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Lymphoma, Non-Hodgkin (3) · Medulloblastoma (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Rhabdoid Tumor (3) · Rhabdomyosarcoma (3) · Sarcoma (3) · Sarcoma, Ewing (3) · Wilms Tumor (3) · Glioblastoma (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Histiocytosis (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (3) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1) · Nuclear Medicine Department, Hospital (1) · Phantoms, Imaging (1) · Temozolomide (1) · Tomography, Optical Coherence (1) · Vinblastine (1) · X-Rays (1) · erdafitinib (1) · ivosidenib (1) · selpercatinib (1) · tipifarnib (1)
National Cancer Institute (NCI) (5) · Northwestern University (1)
United States (6) · Puerto Rico (3) · Australia (2) · Canada (1)
Andrea T Franson (1) · Christine A Pratilas (1) · Daniel C Bowers (1) · Elizabeth D Alva (1) · Karan Dixit, MD (1)
PMID 40675687, PMID 42853672, PMID 42867148
U10CA180886 (4), P30CA060553 (1), UM1CA186644 (1)